August 23, 2016
Patients with severe aortic stenosis and active cancer who undergo transcatheter aortic valve replacement had comparable survival rates compared with patients with severe aortic stenosis but no cancer, independent of cancer status, according to results from the OCEAN-TAVI registry.
In the Japanese, multicenter, prospective registry, researchers evaluated 749 consecutive high-risk patients with severe, symptomatic aortic stenosis who underwent TAVR with the Sapien XT prosthesis (Edwards Lifesciences). Participants were enrolled from eight Japanese hospitals between October 2013 and October 2015. The Valve Academic Research Consortium-2 criteria were used to evaluate procedure success and other procedural factors during TAVR. The researchers defined late mortality as any cause of death after 30 days.